Literature DB >> 15001618

Changes in the serum growth factors and osteoprotegerin after bone marrow transplantation: impact on bone and mineral metabolism.

Ki Hyun Baek1, Won Young Lee, Ki Won Oh, Hye Soo Kim, Je Ho Han, Moo Il Kang, Bong Yun Cha, Kwang Woo Lee, Ho Young Son, Sung Koo Kang, Choon Choo Kim.   

Abstract

The loss of bone mass often occurs after bone marrow transplantation (BMT), particularly during the early posttransplant period. There are few reports on the role of growth factors and osteoprotegerin (OPG) in the post-BMT bone loss. This study prospectively investigated 110 patients undergoing BMT and analyzed 36 patients who had dual-energy x-ray absorptiometry performed before BMT and 1 yr after BMT. The biochemical markers of bone formation and resorption were measured at the short-term intervals during the year-long follow-up. The serum IGF-I, IGF binding protein (IGFBP)-3, fibroblast growth factor-2, macrophage-colony stimulating factor (M-CSF), and OPG levels were measured before and 1 wk, 3 wk, and 3 months after BMT. The mean bone loss in the lumbar spine and the total proximal femur, which was calculated as the percent change from the baseline to the level at 1 yr, was 5.2% (P < 0.05) and 11.6% (P < 0.01), respectively. During the immediate post-BMT period, bone formation decreased, whereas bone resorption increased, which was indicated by the biochemical markers of bone turnover. The serum IGF-I levels also decreased progressively until 3 wk and then increased to the basal values at 3 months. The serum IGFBP-3 levels decreased progressively until 3 months. The serum fibroblast growth factor-2 levels decreased to the nadir at 1 wk and gradually recovered to the basal values at 3 months. The serum M-CSF levels increased immediately after BMT, which declined to its baseline level by 3 months. The serum OPG levels increased progressively, reached a peak at 3 weeks, and declined thereafter. There were significant correlations between the IGF-I and osteocalcin levels before BMT and at 3 wk after BMT (r = 0.45, P < 0.01; r = 0.54, P < 0.01). During the observation period, the serum IGFBP-3 and M-CSF levels showed positive correlations with the osteocalcin and serum collagen I carboxyl-terminal telopeptide levels, respectively. Although statistically not significant, the OPG levels tended to be positively associated with the serum collagen I carboxyl-terminal telopeptide levels. Significant correlations were observed between the percent changes from the baseline to 1 yr in the bone mineral density at the proximal femur and the serum IGF-I levels at 3 wk and 3 months after BMT (r = 0.52, P < 0.01; r = 0.41, P < 0.05).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15001618     DOI: 10.1210/jc.2003-031206

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks.

Authors:  Christopher C Dvorak; Clarisa R Gracia; Jean E Sanders; Edward Y Cheng; K Scott Baker; Michael A Pulsipher; Anna Petryk
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-17       Impact factor: 5.742

2.  Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?

Authors:  K Kananen; L Volin; K Laitinen; T Ruutu; M J Välimäki
Journal:  Osteoporos Int       Date:  2005-12-31       Impact factor: 4.507

3.  Bone mass and microarchitecture of irradiated and bone marrow-transplanted mice: influences of the donor strain.

Authors:  A Dumas; M Brigitte; M F Moreau; F Chrétien; M F Baslé; D Chappard
Journal:  Osteoporos Int       Date:  2008-06-12       Impact factor: 4.507

4.  Modifiable risk factors associated with bone deficits in childhood cancer survivors.

Authors:  Lynda E Polgreen; Anna Petryk; Andrew C Dietz; Alan R Sinaiko; Wendy Leisenring; Pam Goodman; Lyn M Steffen; Joanna L Perkins; Donald R Dengel; K Scott Baker; Julia Steinberger
Journal:  BMC Pediatr       Date:  2012-03-28       Impact factor: 2.125

Review 5.  Bone morbidity in childhood leukemia: epidemiology, mechanisms, diagnosis, and treatment.

Authors:  Sogol Mostoufi-Moab; Jacqueline Halton
Journal:  Curr Osteoporos Rep       Date:  2014-09       Impact factor: 5.096

6.  Changes in bone mineral density and bone turnover markers in patients undergoing hematopoietic stem cell transplant.

Authors:  Aditi Pandit; M K Garg; N Kotwal; K S Brar; Abhay Gundgurthi; A K Sharma; Sanjeevan Sharma
Journal:  Indian J Endocrinol Metab       Date:  2015 May-Jun

Review 7.  Endocrine Disorders in Childhood Cancer Survivors Treated with Haemopoietic Stem Cell Transplantation.

Authors:  Christina Wei; Assunta Albanese
Journal:  Children (Basel)       Date:  2014-06-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.